Literature DB >> 22271447

Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.

George Buchlis1, Gregory M Podsakoff, Antonetta Radu, Sarah M Hawk, Alan W Flake, Federico Mingozzi, Katherine A High.   

Abstract

In previous work we transferred a human factor IX-encoding adeno-associated viral vector (AAV) into skeletal muscle of men with severe hemophilia B. Biopsy of injected muscle up to 1 year after vector injection showed evidence of gene transfer by Southern blot and of protein expression by IHC and immunofluorescent staining. Although the procedure appeared safe, circulating F.IX levels remained subtherapeutic (< 1%). Recently, we obtained muscle tissue from a subject injected 10 years earlier who died of causes unrelated to gene transfer. Using Western blot, IHC, and immunofluorescent staining, we show persistent factor IX expression in injected muscle tissue. F.IX transcripts were detected in injected skeletal muscle using RT-PCR, and isolated whole genomic DNA tested positive for the presence of the transferred AAV vector sequence. This is the longest reported transgene expression to date from a parenterally administered AAV vector, with broad implications for the future of muscle-directed gene transfer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271447      PMCID: PMC3321866          DOI: 10.1182/blood-2011-09-382317

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Authors:  M A Kay; C S Manno; M V Ragni; P J Larson; L B Couto; A McClelland; B Glader; A J Chew; S J Tai; R W Herzog; V Arruda; F Johnson; C Scallan; E Skarsgard; A W Flake; K A High
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

2.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

3.  Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results.

Authors:  Terence R Flotte; Bruce C Trapnell; Margaret Humphries; Brenna Carey; Roberto Calcedo; Farshid Rouhani; Martha Campbell-Thompson; Anthony T Yachnis; Robert A Sandhaus; Noel G McElvaney; Christian Mueller; Louis M Messina; James M Wilson; Mark Brantly; David R Knop; Guo-jie Ye; Jeffrey D Chulay
Journal:  Hum Gene Ther       Date:  2011-08-24       Impact factor: 5.695

4.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

5.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.

Authors:  R W Herzog; J N Hagstrom; S H Kung; S J Tai; J M Wilson; K J Fisher; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice.

Authors:  R O Snyder; S K Spratt; C Lagarde; D Bohl; B Kaspar; B Sloan; L K Cohen; O Danos
Journal:  Hum Gene Ther       Date:  1997-11-01       Impact factor: 5.695

7.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

Authors:  P D Kessler; G M Podsakoff; X Chen; S A McQuiston; P C Colosi; L A Matelis; G J Kurtzman; B J Byrne
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

8.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.

Authors:  Roland W Herzog; Paul A Fields; Valder R Arruda; Jeff O Brubaker; Elina Armstrong; Darryl McClintock; Dwight A Bellinger; Linda B Couto; Timothy C Nichols; Katherine A High
Journal:  Hum Gene Ther       Date:  2002-07-20       Impact factor: 5.695

9.  Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.

Authors:  Valder R Arruda; Joerg Schuettrumpf; Roland W Herzog; Timothy C Nichols; Nancy Robinson; Yasmin Lotfi; Federico Mingozzi; Weidong Xiao; Linda B Couto; Katherine A High
Journal:  Blood       Date:  2003-09-11       Impact factor: 22.113

10.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

View more
  98 in total

1.  [Computer experience and further developments in the respiratory function laboratory (author's transl)].

Authors:  R Schindl; K Mayer; K Aigner
Journal:  Med Klin       Date:  1975-11-07

2.  AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS.

Authors:  Marcel F Leyton-Jaimes; Joy Kahn; Adrian Israelson
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-01       Impact factor: 11.205

3.  Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity.

Authors:  Mickaël Guilbaud; Marie Devaux; Celia Couzinié; Johanne Le Duff; Alice Toromanoff; Céline Vandamme; Nicolas Jaulin; Gwladys Gernoux; Thibaut Larcher; Philippe Moullier; Caroline Le Guiner; Oumeya Adjali
Journal:  Hum Gene Ther       Date:  2019-04-16       Impact factor: 5.695

Review 4.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

5.  Moving forward toward a cure for hemophilia B.

Authors:  Thierry VandenDriessche; Marinee K Chuah
Journal:  Mol Ther       Date:  2015-05       Impact factor: 11.454

6.  Gene therapy for hemophilia: the clot thickens.

Authors:  Katherine A High
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

7.  A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.

Authors:  Yewande Pearse; Michelina Iacovino
Journal:  Med Res Arch       Date:  2020-02-21

8.  CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).

Authors:  Sandra Motas; Virginia Haurigot; Miguel Garcia; Sara Marcó; Albert Ribera; Carles Roca; Xavier Sánchez; Víctor Sánchez; Maria Molas; Joan Bertolin; Luca Maggioni; Xavier León; Jesús Ruberte; Fatima Bosch
Journal:  JCI Insight       Date:  2016-06-16

9.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

Review 10.  Adeno-associated viral vectors for the treatment of hemophilia.

Authors:  Katherine A High; Xavier M Anguela
Journal:  Hum Mol Genet       Date:  2015-11-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.